⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GILD News
Gilead Sciences Inc
Global Experts call for Paradigm Shift in Medicine, Health and Education to Save Lives and Fight Escalating Health Crisis
accessnewswire.com
BMY
MRK
PFE
JNJ
ABBV
AMGN
GILD
REGN
BIIB
LLY
Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
businesswire.com
GILD
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
globenewswire.com
KYMR
GILD
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
businesswire.com
GILD
Prezent Launches Prezent Vivo: The First Communication Partner for Life Sciences that Fuses AI and Experts into One
prnewswire.com
GILD
Form 8-K
sec.gov
GILD
ACLX
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
businesswire.com
GILD
ACLX
U.S. Pharmaceutical Market to Reach USD 965 Billion by 2035
globenewswire.com
ABT
BIIB
BMY
GILD
GSK
LLY
MRK
NVS
NVO
PFE
SNY
AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities
businesswire.com
GILD
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight
globenewswire.com
MRK
IPHA
VERU
KURA
INCY
AMGN
PFE
GILD
REGN
AZN
CRSP
BIIB
NTRA
ALLO
KYMR
ADCT
IMUX
CELC
ONON
ABBV
TDOC
BMY
IMVT
GNTX
IMPP
AUTL